Sales of H. Lundbeck A/S's new migraine prevention therapy, Vyepti (eptinezumab-jjmr), launched in the US in April, were significantly impacted by the COVID-19 pandemic, achieving revenues of only DKK14m ($2.2m) in the first half. But sales of its top four products drove the company’s total revenues up by 5% , with the CNS-focused Danish firm raising its earnings guidance for the year.
Lundbeck's Vyepti Launch In US Disappoints In First Half
But 2020 EBIT Guidance Revised Upwards
The coronavirus pandemic held back sales of Lundbeck’s newest product, Vyepti, in the US during the first half, but the company spent less than expected on SG&A because of COVID-19, and increased investments in marketing infrastructure and restructuring R&D.
More from Earnings
• By
As drugmakers update investors on first quarter financial performance, uncertainty around global trade and US regulatory oversight is likely to dominate discussions.
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
Industry lobbied for pharmaceuticals to be exempt from Trump’s sweeping US tariffs and the effort appears to have paid off. J&J, Lilly and Merck & Co. even got shout outs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
More from Business
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.